Free Trial

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

+0.96 (+1.59%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
94,234 shs
Average Volume
135,761 shs
Market Capitalization
$1.29 billion
P/E Ratio
Dividend Yield
Price Target

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
32.1% Upside
$81.00 Price Target
Short Interest
1.10% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.60mentions of ANI Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$15.19 M Sold Last Quarter
Proj. Earnings Growth
From $3.34 to $3.81 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.68 out of 5 stars

Medical Sector

72nd out of 917 stocks

Pharmaceutical Preparations Industry

25th out of 426 stocks

ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

ANI Pharma Launches Kionex Suspension For Oral Or Rectal Use
ANI: Q1 Earnings Snapshot
ANI Pharmaceuticals, Inc. Q1 Profit Increases, Beats Estimates
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$18.78 million
Pretax Margin


Sales & Book Value

Annual Sales
$486.82 million
Cash Flow
$6.52 per share
Book Value
$21.55 per share


Free Float
Market Cap
$1.29 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Nikhil  LalwaniMr. Nikhil Lalwani (Age 46)
    President, CEO & Director
    Comp: $2.32M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 53)
    Senior VP of Finance & CFO
    Comp: $1.11M
  • Mr. Chad Gassert (Age 48)
    Senior Vice President of Corporate Development & Strategy
    Comp: $849.71k
  • Mr. Christopher K. Mutz (Age 52)
    Senior Vp & Head of Rare Disease
    Comp: $867.92k
  • Mr. Ori Gutwerg (Age 49)
    Senior Vice President of Generics
    Comp: $895.16k
  • Mr. Muthusamy Shanmugam MS R.Ph. (Age 56)
    Head of R&D, COO of Novitium Operations & Director
  • Mr. James G. Marken (Age 61)
    Senior Vice President of Operations & Product Development
    Comp: $673.23k
  • Ms. Meredith W. Cook (Age 49)
    Senior VP, General Counsel & Corporate Secretary
  • Ms. Krista L. Davis (Age 50)
    Senior VP & Chief Human Resources Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease

ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $87.00. On average, they predict the company's stock price to reach $81.00 in the next year. This suggests a possible upside of 32.1% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2024?

ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP stock has increased by 11.2% and is now trading at $61.32.
View the best growth stocks for 2024 here

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ANIP earnings forecast

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The specialty pharmaceutical company had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.15% and a net margin of 6.87%.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY24 earnings guidance on Friday, May, 10th. The company provided earnings per share (EPS) guidance of $4.26-4.67 for the period, compared to the consensus EPS estimate of $4.48. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.14 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.20%), William Blair Investment Management LLC (2.33%), Global Alpha Capital Management Ltd. (1.85%), Kennedy Capital Management LLC (1.00%), Russell Investments Group Ltd. (0.51%) and Principal Financial Group Inc. (0.42%). Insiders that own company stock include Antonio R Pera, Chad Gassert, Christopher Mutz, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Renee P Tannenbaum, Stephen P Carey and Thomas Haughey.
View institutional ownership trends

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 5/25/2024 by Staff

From Our Partners